Loading...
XNAS
QNRX
Market cap7mUSD
Dec 05, Last price  
12.09USD
1D
-36.07%
1Q
59.92%
Jan 2017
-98.41%
Name

Quoin Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XNAS:QNRX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-90.02%
Rev. gr., 5y
%
Revenues
0k
0-280,0000-280,000000000
Net income
-9m
L+3.67%
-2,617,76415,317,00010,172,00015,317,000-1,560,401-1,764,052-8,518,668-9,277,453-8,686,573-9,005,009
CFO
-8m
L-0.09%
-1,984,168-3,767,008-4,978,620-6,573,927-1,298,858-1,338,633-5,720,090-8,480,732-7,864,429-7,857,309

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
URL
https://quoinpharma.com/
IPO date
Nov 01, 1989
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT